Effects of in vivo treatment with ibuprofen on macrophage function in breast and colon cancer patients.
In this study, the capacity of macrophages from breast and colon cancer patients to become cytotoxic for tumor cells after in vivo administration of the prostaglandin inhibitor, Ibuprofen, has been investigated. Prior to the administration of the drug, each patient's macrophages were tested for their ability to kill tumor cells in the presence and absence of 10(-7) M Ibuprofen. The patients were given 400 mg Ibuprofen 4 times daily for 28 days. At days 14 and 28 after commencing the study, blood samples were drawn and the macrophages were tested for their ability to kill tumor cells in vitro. The patients were divided into 3 groups: Category I, patients possessing non-cytotoxic macrophages in the presence and absence of Ibuprofen; Category II, patients possessing non-cytotoxic macrophages in the absence of the drug and cytotoxic macrophages in the presence of the drug; and Category III, patients possessing cytotoxic macrophages in the absence of the drug and non-cytotoxic macrophages in the presence of the drug. Category I cancer patients generally responded the most effectively to in vivo administration of Ibuprofen at day 28 whereas Category II patients responded the most effectively at day 14. Category II patients became non-responsive when tested again at day 28 and Category I patients became non-responsive when the study was extended to day 42. Category III patients were generally non-responsive at all time points studied.(ABSTRACT TRUNCATED AT 250 WORDS)